Christine Dierks, MD

Articles by Christine Dierks, MD

Outcomes Underscore Need for New Agents to Treat Anaplastic Thyroid Carcinoma

March 16th 2021

Christine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.

PD-L1 Expression in Relation to Patients With Thyroid Cancer

ByChristine Dierks, MD

January 13th 2021

Christine Dierks, MD, discusses how PD-L1 expression is used to determine treatment for patients with thyroid cancer.

Early Data Presented for Lenvatinib and Pembrolizumab in Thyroid Cancer

ByChristine Dierks, MD

September 23rd 2020

Christine Dierks, MD, discusses the early data from a study looking at the combination of lenvatinib and pembrolizumab in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.

Pembrolizumab/Lenvatinib Combo Achieves Promising Responses in Anaplastic Thyroid Cancer

ByChristine Dierks, MD

September 19th 2020

Christine Dierks, MD, discusses the results from the prospective phase 2 ATLEP study of lenvatinib in combination with pembrolizumab as treatment of patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.